Comparison of thrombodynamic tests with determination of anti-Xa activity in evaluation of the efficacy of anticoagulant therapy in patients suffering deep vein thrombosis of the lower extremities

Abstract

Deep vein thrombosis of the lower extremities remains an important medical and social problem in practical medicine. Currently, a weight-dependent low-molecular-weight heparin dosing approach is used to treat deep vein thrombosis of the lower extremities in wounded patients without regard to the state of the hemostasis system. This observational study included 30 patients with deep vein thrombosis of the lower extremities who were hospitalized for examination and treatment at the Kirov Military Medical Academy. During treatment with enoxaparin sodium at therapeutic doses, depending on body weight, the parameters of the thrombodynamics test were assessed in all patients, and antiXa activity was determined at the peak of the drug (after 3–4 h) and at the end (before the next injection) of its action. A strong inverse correlation was established between the growth rate indicator of the thrombodynamics test clot and antiXa activity at the peak (–0.777; p < 0.05) and at the end (–0.715; p < 0.05) of the action of sodium enoxaparin. The standard dose of anticoagulant drug, depending on body weight, revealed that 30% of patients were in the hypercoagulation zone, not reaching the target values of the thrombodynamic clot growth rate and anti-Xa activity. The thrombodynamics test results identified the growth rate of the test clot with antiXa activity, which allows both methods to be considered comparable for laboratory monitoring low-molecular-weight heparin therapy in wounded individuals. The insufficient anticoagulant effect in one-third of the injured individuals that received the standard and therapeutic doses of low-molecular-weight heparins requires the development of a personalized approach to titration of low-molecular-weight heparins, which may be based not on the concentration of the drug per body weight but on the achieved anticoagulant effect that optimizes the treatment outcomes and patient prognosis. Accordingly, further research is required.

Keywords

deep vein thrombosis / low molecular weight heparins / anti-Хa activity / thrombodynamics / clot growth rate / monitoring of anticoagulant therapy / wounded / a personalized approach

References

[1] Petrov AN, Borisov MB, Denisenko VV, et al. Prevention of acute thromboembolic events in patients with multistage surgical treatment was combined skeletal trauma. Emergency medical care. 2016;17(2):42–48. EDN: VZZPJT

[2] Петров А.Н., Борисов М.Б., Денисенко В.В., и др. Профилактика острых тромбоэмболических осложнений у пострадавших многоэтапным хирургическим лечением сочетанной скелетной травмы // Скорая медицинская помощь. 2016. Т. 17, № 2. С. 42–48. EDN: VZZPJT

[3] Petrov AN, Borisov MB, Denisenko VV, et al. Prevention of acute thromboembolic events in patients with multistage surgical treatment was combined skeletal trauma. Emergency medical care. 2016;17(2):42–48. EDN: VZZPJT

[4] Salukhov VV, Kharitonov MA, Varavin NA, et al. Impact of stress on hemostasis: a review. Consilium Medicum. 2023;25(2):91–94. EDN: UMERGA doi: 10.26442/20751753.2023.2.202183

[5] Салухов В.В., Харитонов М.А., Варавин Н.А., и др. Влияние стресса на гемостаз // Consilium Medicum. 2023. Т. 25, № 2. C. 91–94. EDN: UMERGA doi: 10.26442/20751753.2023.2.202183

[6] Salukhov VV, Kharitonov MA, Varavin NA, et al. Impact of stress on hemostasis: a review. Consilium Medicum. 2023;25(2):91–94. EDN: UMERGA doi: 10.26442/20751753.2023.2.202183

[7] Tingting W, Xiaotong X, Wenjun Ch, et al. The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: A systematic review and meta-analysis. J Clin Pharm Ther. 2020;45(4):602–608. doi: 10.1111/jcpt.13169

[8] Tingting W., Xiaotong X., Wenjun Ch., et al. The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: A systematic review and meta-analysis // J Clin Pharm Ther. 2020. Vol. 45, N. 4. P. 602–608. doi: 10.1111/jcpt.13169

[9] Tingting W, Xiaotong X, Wenjun Ch, et al. The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: A systematic review and meta-analysis. J Clin Pharm Ther. 2020;45(4):602–608. doi: 10.1111/jcpt.13169

[10] Dementeva GI, Lobastov KV, Skopintsev VB, Laberko LA. The possibility of global assessment tests of the hemostatic system in the prediction of venous thromboembolism in surgical practice. Surgeon. 2017;(4):27–38. EDN: VYWCFD

[11] Дементьева Г.И., Лобастов К.В., Скопинцев В.Б. Лаберко Л.А. Возможности глобальных тестов оценки системы гемостаза в прогнозировании венозных тромбоэмболических осложнений в хирургической практике // Хирург. 2017. № 4. С. 27–38. EDN: VYWCFD

[12] Dementeva GI, Lobastov KV, Skopintsev VB, Laberko LA. The possibility of global assessment tests of the hemostatic system in the prediction of venous thromboembolism in surgical practice. Surgeon. 2017;(4):27–38. EDN: VYWCFD

[13] Sebaaly J, Covert K. Enoxaparin dosing at extremes of weight: literature review and dosing recommendations. Ann Pharmacother. 2018;52(9):898–909. doi: 10.1177/1060028018768449

[14] Sebaaly J., Covert K. Enoxaparin dosing at extremes of weight: literature review and dosing recommendations // Ann Pharmacother. 2018. Vol. 52, N. 9. P. 898–909. doi: 10.1177/1060028018768449

[15] Sebaaly J, Covert K. Enoxaparin dosing at extremes of weight: literature review and dosing recommendations. Ann Pharmacother. 2018;52(9):898–909. doi: 10.1177/1060028018768449

[16] Gebekova ZA, Ivanov II, Asambayeva A, et al. Thrombodynamics test in assessing the risk of thrombus formation in patients with atrial fibrillation taking direct oral anticoagulants. Rational Pharmacotherapy in Cardiology. 2022;18(5):544–552. EDN: CNDQLK doi: 10.20996/1819-6446-2022-09-07

[17] Гебекова З.А., Иванов И.И., Асамбаева А., и др. Тест «Тромбодинамика» в оценке риска тромбообразования у пациентов с фибрилляцией предсердий, получающих прямые оральные антикоагулянты // Рациональная фармакотерапия в кардиологии. 2022. Т. 18, № 5. С. 544–552. EDN: CNDQLK doi: 10.20996/1819-6446-2022-09-07

[18] Gebekova ZA, Ivanov II, Asambayeva A, et al. Thrombodynamics test in assessing the risk of thrombus formation in patients with atrial fibrillation taking direct oral anticoagulants. Rational Pharmacotherapy in Cardiology. 2022;18(5):544–552. EDN: CNDQLK doi: 10.20996/1819-6446-2022-09-07

[19] Krechetova LV, Nechipurenko DY, Shpilyuk MA, et al. The use of the thrombodynamics test in the diagnostics of hemostasis disorders in patients with COVID-19 of varying severity. Journal of Clinical Practice. 2021;12(4):23–37. EDN: LYZSSG doi: 10.17816/clinpract88138

[20] Кречетова Л.В., Нечипуренко Д.Ю., Шпилюк М.А., и др. Использование теста тромбодинамики в диагностике нарушений гемостаза у больных COVID-19 разной степени тяжести // Клиническая практика. 2021. Т. 12, № 4. C. 23–37. EDN: LYZSSG doi: 10.17816/clinpract88138

[21] Krechetova LV, Nechipurenko DY, Shpilyuk MA, et al. The use of the thrombodynamics test in the diagnostics of hemostasis disorders in patients with COVID-19 of varying severity. Journal of Clinical Practice. 2021;12(4):23–37. EDN: LYZSSG doi: 10.17816/clinpract88138

[22] Startseva ON, Vavilova TV, Kornev VI, Zybina NN. Laboratory evaluation of the anticoagulant therapy effect: comparative characteristics of the thrombodynamics assay and anti-Xa activity measurement. Preventive and clinical medicine. 2023;(2):97–102. EDN: WLXWGW doi: 10.47843/2074--9120_2023_2_97

[23] Старцева О.Н., Вавилова Т.В., Корнев В.И., Зыбина Н.Н. Лабораторная оценка эффекта антикоагулянтной терапии: сравнительная характеристика теста тромбодинамика и определения анти-Ха активности // Профилактическая и клиническая медицина. 2023. № 2. С. 97–102. EDN: WLXWGW doi: 10.47843/2074--9120_2023_2_97

[24] Startseva ON, Vavilova TV, Kornev VI, Zybina NN. Laboratory evaluation of the anticoagulant therapy effect: comparative characteristics of the thrombodynamics assay and anti-Xa activity measurement. Preventive and clinical medicine. 2023;(2):97–102. EDN: WLXWGW doi: 10.47843/2074--9120_2023_2_97

[25] Bitsadze VO, Slukhanchuk EV, Khizroeva JKh, et al. Anticoagulants: dose control methods and inhibitors. Obstetrics, Gynecology and Reproduction. 2022;16(2):158–175. EDN: FUDDQK doi: 10.17749/2313-7347/ob.gyn.rep.2022.293

[26] Бицадзе В.О., Слуханчук Е.В., Хизроева Д.Х., и др. Антикоагулянты: методы контроля дозы и ингибиторы // Акушерство, гинекология и репродукция. 2022. Т. 16, № 2. С. 158–175. EDN: FUDDQK doi: 10.17749/2313-7347/ob.gyn.rep.2022.293

[27] Bitsadze VO, Slukhanchuk EV, Khizroeva JKh, et al. Anticoagulants: dose control methods and inhibitors. Obstetrics, Gynecology and Reproduction. 2022;16(2):158–175. EDN: FUDDQK doi: 10.17749/2313-7347/ob.gyn.rep.2022.293

[28] Dorokhina EV, Salukhov VV. Methodology of comprehensive assessment of coagulation complications and correction of anti-coagulant therapy of new coronaroviral infection COVID-19. Russian Military Medical Academy Reports. 2021;40(S1-3):85–92. EDN: ZKEEFA

[29] Салухов В.В., Дорохина Е.В. Методология комплексной оценки коагуляционных осложнений и коррекции антикоагулянтной терапии новой коронавирусной инфекции СOVID-19 // Известия Российской военно-медицинской академии. 2021. Т. 40, № S1-3. C. 85–92. EDN: ZKEEFA

[30] Dorokhina EV, Salukhov VV. Methodology of comprehensive assessment of coagulation complications and correction of anti-coagulant therapy of new coronaroviral infection COVID-19. Russian Military Medical Academy Reports. 2021;40(S1-3):85–92. EDN: ZKEEFA

[31] Petrov VI, Shatalova OV, Maslakov AS, Kushkinova AV. Monitoring of anticoagulant therapy in patients with deep vein thrombosis. Cardiovascular Therapy and Prevention. 2014;13(4):54–59. EDN: SLQTTV doi: 10.15829/1728-8800-2014-4-54-59

[32] Петров В.И., Шаталова О.В., Маслаков А.С., Кушкинова А.В. Мониторинг антикоагулянтной терапии у пациентов с тромбозом глубоких вен // Кардиоваскулярная терапия и профилактика. 2014. Т. 13, № 4. С. 54–59. EDN: SLQTTV doi: 10.15829/1728-8800-2014-4-54-59

[33] Petrov VI, Shatalova OV, Maslakov AS, Kushkinova AV. Monitoring of anticoagulant therapy in patients with deep vein thrombosis. Cardiovascular Therapy and Prevention. 2014;13(4):54–59. EDN: SLQTTV doi: 10.15829/1728-8800-2014-4-54-59

[34] Ketsko YuL, Tereshina OV. nticoagulant therapy monitoring in COVID-19 patients in the intensive care unit: thromboelastometry and echocardiography. Russian Journal of Cardiology. 2022;27(1):74–81. EDN: MFPSSL doi: 10.15829/1560-4071-2022-4844

[35] Кецко Ю.Л., Терешина О.В. Возможность мониторинга антикоагулянтной терапии у пациентов с COVID-19 в отделении реанимации и интенсивной терапии: тромбоэластометрия и эхокардиография // Российский кардиологический журнал. 2022. Т. 27, № 1. C. 74–81. EDN: MFPSSL doi: 10.15829/1560-4071-2022-4844

[36] Ketsko YuL, Tereshina OV. nticoagulant therapy monitoring in COVID-19 patients in the intensive care unit: thromboelastometry and echocardiography. Russian Journal of Cardiology. 2022;27(1):74–81. EDN: MFPSSL doi: 10.15829/1560-4071-2022-4844

[37] Lobanova TN, Sharapov GN, Esipov AV, et al. The role thromboelastogram in the diagnosis and monitoring of the new coronavirus infection COVID-19 in the hospital conditions of the 3 CMCH named after A.A. Vishnevsky. Hospital medicine: science and practice. 2021;4(4): 80–87. EDN: RBGLVL doi: 10.34852/GM3CVKG.2021.11.60.014

[38] Лобанова Т.Н., Шарапов Г.Н., Есипов А.В., и др. Роль ТЭГ в диагностике и мониторинге новой коронавирусной инфекции COVID-19 в условиях стационара 3 ЦВКГ им. А.А. Вишневского // Госпитальная медицина: наука и практика. 2021. Т. 4, № 4. С. 80–87. EDN: RBGLVL doi: 10.34852/GM3CVKG.2021.11.60.014

[39] Lobanova TN, Sharapov GN, Esipov AV, et al. The role thromboelastogram in the diagnosis and monitoring of the new coronavirus infection COVID-19 in the hospital conditions of the 3 CMCH named after A.A. Vishnevsky. Hospital medicine: science and practice. 2021;4(4): 80–87. EDN: RBGLVL doi: 10.34852/GM3CVKG.2021.11.60.014

[40] Vermeiren P, Vandevelde A, Peperstraete H, Devreese KMJ. Monitoring of heparin therapy beyond the anti-Xa activity assay: Evaluation of a thrombin generation assay. Int J Lab Hematol. 2022;44(4):785–795. doi: 10.1111/ijlh.13836

[41] Vermeiren P., Vandevelde A., Peperstraete H., Devreese K.M.J. Monitoring of heparin therapy beyond the anti-Xa activity assay: Evaluation of a thrombin generation assay // Int J Lab Hematol. 2022. Vol. 44, N. 4. P. 785–795. doi: 10.1111/ijlh.13836

[42] Vermeiren P, Vandevelde A, Peperstraete H, Devreese KMJ. Monitoring of heparin therapy beyond the anti-Xa activity assay: Evaluation of a thrombin generation assay. Int J Lab Hematol. 2022;44(4):785–795. doi: 10.1111/ijlh.13836

[43] Centeno EH, Militello M, Gomes MP. Anti-Xa assays: what is their role today in antithrombotic therapy? Cleve Clin J Med. 2019;86(6):417–425. doi: 10.3949/ccjm.86a.18029

[44] Centeno E.H., Militello M., Gomes M.P. Anti-Xa assays: what is their role today in antithrombotic therapy? // Cleve Clin J Med. 2019. Vol. 86, N. 6. P. 417–425. doi: 10.3949/ccjm.86a.18029

[45] Centeno EH, Militello M, Gomes MP. Anti-Xa assays: what is their role today in antithrombotic therapy? Cleve Clin J Med. 2019;86(6):417–425. doi: 10.3949/ccjm.86a.18029

[46] Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257–3291. doi: 10.1182/bloodadvances.2018024893

[47] Witt D.M., Nieuwlaat R., Clark N.P., et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy // Blood Adv. 2018. Vol. 2, N. 22. P. 3257–3291. doi: 10.1182/bloodadvances.2018024893

[48] Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257–3291. doi: 10.1182/bloodadvances.2018024893

[49] Taylor A, Huang E, Waller J, et al. Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients. Pharmacotherapy. 2021;41(6):508–514. doi: 10.1002/phar.25262

[50] Taylor A., Huang E., Waller J., et al. Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients // Pharmacotherapy. 2021. Vol. 41, N. 6. P. 508–514. doi: 10.1002/phar.25262

[51] Taylor A, Huang E, Waller J, et al. Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients. Pharmacotherapy. 2021;41(6):508–514. doi: 10.1002/phar.25262

[52] Trunfio M, Salvador E, Cabodi D, et al. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. Thromb Res. 2020;196:432–434. doi: 10.1016/j.thromres.2020.09.039

[53] Trunfio M., Salvador E., Cabodi D., et al. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection // Thromb Res. 2020. Vol. 196. P. 432–434. doi: 10.1016/j.thromres.2020.09.039

[54] Trunfio M, Salvador E, Cabodi D, et al. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. Thromb Res. 2020;196:432–434. doi: 10.1016/j.thromres.2020.09.039

[55] Varavin NA, Salukhov VV, Kryukov EV, Kolodyazhnaya VA. Comparative evaluation of preventive anticoagulant therapy regimens in the wounded. Medical Council. 2023;17(13):305–311. EDN: GRLLRL doi: 10.21518/ms2023-196

[56] Варавин Н.А., Салухов В.В., Крюков Е.В., Колодяжная В.А. Сравнительная оценка режимов профилактической антикоагулянтной терапии у раненых // Медицинский совет. 2023. Т. 17, № 13. С. 305–311. EDN: GRLLRL doi: 10.21518/ms2023-196

[57] Varavin NA, Salukhov VV, Kryukov EV, Kolodyazhnaya VA. Comparative evaluation of preventive anticoagulant therapy regimens in the wounded. Medical Council. 2023;17(13):305–311. EDN: GRLLRL doi: 10.21518/ms2023-196

[58] Varavin NA, Salukhov VV, Gavrilov EK. Venous thromboembolic disordersin the wounded: design of the prospective study “OPRAVA”. Medical Bulletin of the Ministry of Internal Affairs. 2023;125(4):43–46. EDN: XOICZG

[59] Варавин Н.А., Салухов В.В., Гаврилов Е.К. Венозные тромбоэмболические осложнения у раненых: дизайн проспективного исследования «ОПРАВА» // Медицинский вестник МВД. 2023. Т. 125, № 4. С. 43–46. EDN: XOICZG

[60] Varavin NA, Salukhov VV, Gavrilov EK. Venous thromboembolic disordersin the wounded: design of the prospective study “OPRAVA”. Medical Bulletin of the Ministry of Internal Affairs. 2023;125(4):43–46. EDN: XOICZG

RIGHTS & PERMISSIONS

Eco-Vector